Journal of thoracic disease最新文献

{"title":"Uniportal video-assisted thoracoscopic thymectomy in Hospital Kuala Lumpur: a retrospective observational review of outcomes for patients diagnosed with thymomatous and non-thymomatous myasthenia gravis.","authors":"Dinesh Francis K Balasingam, Benedict Dharmaraj, Diong Nguk Chai, Narendran Balasubbiah, Palaniappan Meiyappan, Narasimman Sathiamurthy","doi":"10.21037/jtd-24-830","DOIUrl":"https://doi.org/10.21037/jtd-24-830","url":null,"abstract":"<p><strong>Background: </strong>The standard treatment for thymomatous myasthenia gravis (TMG) patients is thymectomy, whereas its role in non-TMG (NTMG) is still under debate. The objective of this study is to assess myasthenia gravis (MG) outcomes of thymectomy using the uniportal video-assisted thoracoscopic surgery (UVATS) technique for both groups and evaluate the procedure's efficacy and safety.</p><p><strong>Methods: </strong>We retrospectively collected data from January 2019 to December 2022 at Hospital Kuala Lumpur. The Myasthenia Gravis Activities of Daily Living (MG-ADL) scoring and the Myasthenia Gravis Foundation of America's Post Interventional Score (MGFA-PIS) measured our primary outcome. Secondary outcomes included surgery-related morbidity. All patients underwent a UVATS thymectomy, with the incision at the right anterior axillary line at the 5^th intercostal space.</p><p><strong>Results: </strong>Out of 26 patients, 22 were analysed. The MG-ADL scores indicated a significant mean score reduction post-surgery [6.9; 95% confidence interval (CI): 4.42 to 9.67; P<0.001]. NTMG patients exhibited a greater decrease in MG-ADL mean score than TMG patients {9.5 [standard deviation (SD) 4.8] <i>vs</i>. 6.1 (SD 5.4) P<0.001}. The MGFA-PIS showed complete stable remission (CSR) rates of 43% for TMG and 25% for NTMG patients. Surgical morbidity was observed in 13% of patients, of which were myasthenic crisis, difficult extubation due to carbon dioxide (CO₂) retention and subcutaneous emphysema.</p><p><strong>Conclusions: </strong>Thymectomy via UVATS is an effective and safe approach for improving symptoms in both TMG and NTMG patients.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"16 11","pages":"7446-7457"},"PeriodicalIF":2.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of percutaneous mechanical thrombectomy in the treatment of acute medium- or high-risk pulmonary embolism: a single-center retrospective cross-sectional study.","authors":"Fei Li, Zhengxian Su, Chuntao Fu, Qing Wang, Xiang Wang, Jiecheng Zhang, Masahiro Yanagiya, Wenjun Zhao","doi":"10.21037/jtd-24-1690","DOIUrl":"10.21037/jtd-24-1690","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Patients with acute and high-risk pulmonary embolism have a high mortality rate, and the optimal treatment for these patients has still not been fully established. Although anticoagulation therapy is currently the preferred treatment for pulmonary embolism, for some patients with intermediate- or high-risk pulmonary embolism, anticoagulation therapy alone has a higher probability of long-term pulmonary hypertension and also seriously worsens the quality of life of patients. This paper mainly reports the efficacy and safety of percutaneous mechanical thrombectomy (PMT) in patients with acute medium- or high-risk pulmonary embolism in Taizhou Hospital of Zhejiang Province so as to provide some clinical basis for the treatment of such patients in the future.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study mainly collected the clinical data of 43 patients who were admitted to Taizhou Hospital of Zhejiang Province from May 2018 to May 2023 due to acute medium-to-high-risk pulmonary embolism and received PMT treatment. Preoperative and postoperative blood tests, vital signs, and echocardiographic parameters were compared. The incidence of intraoperative and postoperative complications in follow-up at 1, 6, and 12 months was also recorded. Mechanical treatment included thrombus fragmentation complemented with aspiration.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among the 43 patients, 22 patients were treated with thrombus fragmentation coupled with a pigtail catheter and aspiration using a 6-F multipurpose angiographic (MPA) catheter, 11 were treated by AngioJet, and 10 were treated with an AcoStream catheter. Local thrombolysis treatment with small dose of urokinase was administered in some patients according to the patient's risk of bleeding. Among the patients, 41 patients received a successful operation, representing a surgical success rate of 95.3%. There was one patient with pulmonary infection who died after discharge. There were significant differences in vital signs between the 48-hour preoperative timepoint and the 48-hour postoperative timepoint including cardiac index, pulse, mean arterial pressure, and oxygen saturation (P&lt;0.001). The blood test indicators of carbon dioxide partial pressure and creatinine level did not show obvious abnormalities, but differences in hemoglobin, oxygen partial pressure, and lactate level were statistically significant. In terms of cardiac ultrasound, pulmonary artery pressure and right atrial diameter change were significantly different (P&lt;0.001). There were seven cases of local hematoma at the puncture site, three cases of infection at the puncture site, and nine cases of transient cardiac arrest during the operation. All 41 patients were followed up: one patient died after being discharged due to aggravation of pulmonary infection during hospitalization, one patient died of intracerebral hemorrhage 9 months after the operation, one patient developed recurrent pulmonary embolism, and five p","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"16 11","pages":"7797-7806"},"PeriodicalIF":2.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myeloprotection effects of trilaciclib in Chinese patients with extensive stage small cell lung cancer (ES-SCLC) receiving chemotherapy-a real-world study.","authors":"Yongxing Chen, Chong Meng, Lirong Liu, Kai Liu, Tao Chen, Chen Yang","doi":"10.21037/jtd-24-893","DOIUrl":"10.21037/jtd-24-893","url":null,"abstract":"<p><strong>Background: </strong>Trilaciclib, an intravenous short acting cyclin-dependent kinase 4/6 inhibitor, has been approved for the prevention of chemotherapy-induced myelosuppression (CIM) in patients with extensive stage small cell lung cancer (ES-SCLC) receiving platinum/etoposide (EP) or topotecan (TPT)-based therapy in United States (US) since February 2021. Trilaciclib use received the priority review and approval in a real-world setting in China. This study thus aimed to collect real-world data and evaluate the protective effect of trilaciclib on CIM in Chinese patients with ES-SCLC.</p><p><strong>Methods: </strong>This single-arm, noninterventional real world study invited all patients with ES-SCLC who received trilaciclib with the platinum and etoposide ± anti-programmed cell death ligand-1 [anti-PD-(L)1] antibodies (EP group) or trilaciclib with TPT (TPT group) in Boao, Hainan China to participate in the study. The primary endpoint was the incidence of the severe (grade four) neutropenia (SN), and the secondary endpoints included other myeloprotection effects, safety and anti-tumor activity.</p><p><strong>Results: </strong>Between August 2021 and December 2022, a total of 30 patients who received trilaciclib with chemotherapy consented to participate in this real-world study. Among the enrolled patients, 26 patients were treated with EP regimen, of these, 18 patients were combined with anti-PD-(L)1 antibodies, and 4 patients were treated with TPT. The incidence of SN was 6.7%, with one patient each in EP group and TPT group. The incidence of grade three hematological toxicities was 30% (9/30), with 19.2% (5/26) in the EP group, and 100% (4/4) in the TPT group. The incidence of grade four hematological toxicities was 5/30 (16.7%), with 3/26 (11.5%) and 2/4 (50%) in EP and TPT group, respectively. Overall, the incidence of those who received intravenous or oral antibiotics was 6/30 (20%), with 4/26 (15.4%) in the EP group, and 2/4 (50%) in the TPT group. No ≥ grade three adverse events, serious adverse events (SAEs), and adverse events of special interest associated with trilaciclib were reported.</p><p><strong>Conclusions: </strong>Trilaciclib decreased the incidence of CIM in Chinese patients when administered prior to an EP-containing regimen [combined with or without PD-(L)1] or TPT for ES-SCLC. The effect of myeloprotection, anti-tumor and safety were all consistent with the studies conducted globally and data from the Chinese Phase three placebo-controlled study (TRACES).</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"16 11","pages":"7233-7243"},"PeriodicalIF":2.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraoperative transbronchial metallic coil marking guided by mobile 3D C-arm for resection of a small peripheral lung lesion.","authors":"Hiromitsu Takizawa, Naoki Miyamoto, Naoya Kawakita, Taihei Takeuchi, Shinichi Sakamoto, Hiroyuki Sumitomo, Atsushi Morishita, Hiroaki Toba","doi":"10.21037/jtd-24-951","DOIUrl":"10.21037/jtd-24-951","url":null,"abstract":"<p><p>Sublober resection of small peripheral lung lesions using video-assisted thoracoscopic surgery may require marking and confirmation using 3D imaging in the interventional radiology suite or in the hybrid operating room (HOR) before surgery is started. We report a novel approach for intraoperative transbronchial metallic coil marking followed by thoracoscopic wedge resection in a conventional operating room under mobile 3D C-arm guidance. Under general anesthesia, an ultrathin video-bronchoscope was inserted into an objective bronchus guided with virtual bronchoscopic navigation, and a coil-feeding microcatheter was introduced through the bronchoscope's channel. After the position of the catheter tip was confirmed with cone-beam computed tomography (CT) images rendered via a mobile 3D C-arm, a metallic coil was subsequently deployed through the catheter as a marker. During surgery, the nodule with the metallic coil was grasped with pulmonary forceps and fully resected with endostaplers under fluoroscopic guidance. This method has advantages because the transbronchial approach carries a lower risk of complications such as pneumothorax and air embolism compared with a percutaneous approach, and the metallic coil provides more accurate, pinpoint localization compared with liquid dye. Mobile 3D C-arm-guided transbronchial metallic coil marking followed by thoracoscopic wedge resection under fluoroscopic guidance is a one-stop solution for intraoperative marking and resection of small peripheral pulmonary lesions in any operating room.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"16 11","pages":"7933-7940"},"PeriodicalIF":2.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"17-hydroxy-jolkinolide B potentiated CTLA4ab therapy through targeting tumor suppression and immune activation by downregulating PD-L1 expression in lung adenocarcinoma.","authors":"Xuewei Chen, Yingxin Chen, Jieyu Xie, Junjun Fu, Xin Zhang","doi":"10.21037/jtd-24-781","DOIUrl":"10.21037/jtd-24-781","url":null,"abstract":"<p><strong>Background: </strong>17-hydroxy-jolkinolide B (HJB) is a natural diterpenoid compound derived from plants of the <i>Euphorbiaceae</i> family that has anticancer properties against various types of tumors. However, its action and underlying mechanism in lung adenocarcinoma (LUAD) progression remain largely unknown. Thus, this research aimed to explore the role of HJB in LUAD pathogenesis and its clinical significance in tumor therapy.</p><p><strong>Methods: </strong>Cell Counting Kit-8 (CCK-8) assay, colony formation assay, and scratch wound-healing assay were utilized to evaluate the effect of HJB on proliferation, colony formation, and migration of LUAD cells <i>in vitro</i>. The syngeneic and xenograft tumor models were used to evaluate the anti-tumor activity of HJB in combination with cytotoxic T-lymphocyte antigen 4 antibody (CTLA4ab) on LUAD <i>in vivo</i>. In addition, quantitative real-time polymerase chain reaction (qPCR) and western blotting analyses were used to analyze the expression of programmed death ligand 1 (PD-L1). Lentiviral transduction and transfection were used to explore the related mechanism.</p><p><strong>Results: </strong>Experimental data demonstrated that HJB inhibited cell viability, colony formation, and migration of murine and human LUAD cells <i>in vitro</i>. The syngeneic and xenograft tumor models indicated that HJB possessed a remarkable anti-tumor activity <i>in vivo</i> and potentiated immune checkpoint blockades (ICBs) therapy. Moreover, PD-L1 might serve as a novel target in HJB-suppressed lung cancer.</p><p><strong>Conclusions: </strong>By targeting PD-L1, HJB inhibited tumor cell proliferation and colony formation, as well as migration ability <i>in vitro</i> and <i>in vivo</i>. Besides, HJB enhanced CTLA4ab therapy and may be a potential agent for LUAD therapy.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"16 11","pages":"7526-7538"},"PeriodicalIF":2.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of impaired lung diffusion capacity in COVID-19 pneumonia survivors.","authors":"Olga I Savushkina, Elena S Muraveva, Irina V Zhitareva, Galina V Nekludova, Malika Kh Mustafina, Sergey N Avdeev","doi":"10.21037/jtd-24-1118","DOIUrl":"https://doi.org/10.21037/jtd-24-1118","url":null,"abstract":"<p><strong>Background: </strong>Patients surviving the coronavirus disease 2019 (COVID-19) are reported to explore pulmonary sequelae. It is challenging to provide pulmonary function tests (PFTs) during the pandemic of this contagious diseases because of the difficulty related to infection control risks. This study aims to identify important predictors of lung diffusion capacity impairment in COVID-19 survivors after hospital discharge.</p><p><strong>Methods: </strong>The retrospective cohort study included 341 patients after COVID-19. The parameters of spirometry, body plethysmography, lung diffusion capacity for carbon monoxide (DLco), and the worst chest computed tomography (CT) scan in the acute phase of COVID-19 (CT_max, %) were assessed. Multivariable logistic regression analysis for exploring risk factors associated with lung diffusion capacity impairment was used. The receiver operating characteristic (ROC) curve of multivariate observation and the area under the curve (AUC) were used to assess the performance of a model.</p><p><strong>Results: </strong>At the time of the analysis, 64.8% (221/341) patients participated in follow-up visits on 90 days, 23.5% (80/341) on 90-180 days, and 11.7% (40/341) on more than 180 days after the onset of COVID-19 symptoms. The median CT_max was 50% (50% of the lung area was involved in a pathological process according to a semi-quantitative CT score). Abnormal DLco (<80% of predicted) was recorded in 60.4% cases. The predictors such as age, gender, body mass index (BMI), CT_max, and the time interval between the COVID-19 symptoms onset and follow-up PFTs were encapsulated in the logistic regression analysis to explore the prediction of reduced DLco. Backward stepwise regression was applied to eliminate insignificant predictors. It was found that CT_max was important predictor of impaired DLco. AUC value was 0.780 [95% confidential interval (CI): 0.723-0.837, P<0.001]. The sensitivity and specificity in the training group were 80% and 67%, respectively. The odds ratio (OR) showed that CT_max =45% and more in the acute phase of COVID-19 was significantly associated with reduced DLco during 6 months after COVID-19 (OR 1.21, 95% CI: 1.095-1.334; P<0.05).</p><p><strong>Conclusions: </strong>Pulmonary interstitial damage caused by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) definitely contributes to reduced DLco after hospital discharge. This indicates that analysis of CT scans during the acute phase of COVID-19 may have prognostic relevance for abnormal DLco.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"16 11","pages":"7282-7289"},"PeriodicalIF":2.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival and prognosis after surgical treatment of patients with thymic carcinoma: a retrospective analysis.","authors":"Kai Zhao, Yiming Liu, Miao Jing, Wenhan Cai, Jiamei Jin, Zirui Zhu, Jiaxin Wen, Zhiqiang Xue","doi":"10.21037/jtd-24-1056","DOIUrl":"10.21037/jtd-24-1056","url":null,"abstract":"<p><strong>Background: </strong>Thymic carcinoma is a type of rare and highly malignant tumor that originates from the thymic epithelium. Treatment and prognosis of thymic carcinoma remain controversial. We retrospectively analyzed survival data from a large sample database in a single center in China to summarize the clinicopathological features of patients with thymic carcinoma and explore the factors affecting prognosis.</p><p><strong>Methods: </strong>The clinical data of 87 patients with thymic carcinoma who underwent surgical treatment between January 2010 and October 2023 were retrospectively analyzed. Of these, 74 patients had thymic squamous cell carcinoma, and 13 had other subtypes. The Kaplan-Meier method was used to calculate survival rate, and the log-rank test was employed for univariate analysis. The Cox proportional hazards regression model was used for multivariate analysis to evaluate the clinical, pathological, and therapeutic information of patients with thymic carcinoma, analyze long-term survival, and identify prognostic factors associated with postoperative thymic carcinoma.</p><p><strong>Results: </strong>The 5- and 10-year overall survival (OS) rates were 85.6% and 69.9%, respectively, and the corresponding disease-free survival (DFS) rates were 76.4% and 58.6%, respectively. Univariate analysis revealed significant associations between the Masaoka-Koga stage, resection status, postoperative radiotherapy, and OS in patients with thymic carcinoma. Furthermore, the Masaoka-Koga stage is correlated with DFS in patients who underwent postoperative treatment for thymic carcinoma. Cox multivariate analysis confirmed that the Masaoka-Koga stage [hazard ratio (HR): 2.719, 95% confidence interval (CI): 1.032-7.163, P=0.043] independently influenced DFS in surgically treated patients with thymic carcinoma, whereas the Masaoka-Koga stage (HR: 3.690, 95% CI: 1.043-13.049, P=0.043) and postoperative radiotherapy (HR: 0.319, 95% CI: 0.102-0.999, P=0.049) emerged as critical prognostic factors affecting OS.</p><p><strong>Conclusions: </strong>Thymic squamous cell carcinoma is the most prevalent form of thymic carcinoma, and complete resection (R0 resection) is the preferred treatment modality. The Masaoka-Koga stage and postoperative radiotherapy are significant prognostic indicators for improved outcomes.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"16 11","pages":"7582-7591"},"PeriodicalIF":2.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of watershed analysis with indocyanine green fluorescence staining and modified inflation-deflation method in single-port thoracoscopic complex pulmonary segmentectomy.","authors":"Yongsen Li, Yonghao Cao, Yuan Chen, Jing Huang, Kunpeng Feng, Chun Xu, Chang Li, Jun Zhao, Ziqing Shen, Cheng Ding","doi":"10.21037/jtd-24-1075","DOIUrl":"10.21037/jtd-24-1075","url":null,"abstract":"<p><strong>Background: </strong>The increasing utilization of computed tomography (CT) scans has significantly elevated the detection rate of pulmonary nodules. Pulmonary segmentectomy has become the preferred surgical technique for peripheral non-small cell lung cancer (NSCLC) measuring 2 cm or smaller. Various methods for identifying the intersegmental planes (ISPs) are currently employed. This study aims to compare the short-term clinical safety and efficacy of the watershed analysis with indocyanine green (ICG) fluorescence staining to the modified inflation-deflation method in single-port thoracoscopic complex pulmonary segmentectomy.</p><p><strong>Methods: </strong>This retrospective study was conducted on patients who underwent single-port thoracoscopic complex pulmonary segmentectomy at The First Affiliated Hospital of Soochow University between January 2023 and December 2023. One cohort received treatment with the watershed analysis with ICG fluorescence staining, while the other cohort was treated with the modified inflation-deflation method. The study evaluated intraoperative and postoperative conditions, as well as the short-term impact on postoperative pulmonary function in both groups.</p><p><strong>Results: </strong>The watershed analysis with ICG fluorescence staining group demonstrated less operating time (P<0.001), shorter ISPs visualization time (P<0.001), and reduced intraoperative blood loss (P<0.001). Postoperatively, 8 patients (16%) in this group experienced air leakage, compared to 20 patients (39%) in the modified inflation-deflation method group, indicating significant differences between the groups (P=0.009). Additionally, the watershed analysis with ICG fluorescence staining group had shorter postoperative drainage tube duration (P<0.001), shorter postoperative hospitalization (P<0.001), and less postoperative pleural effusion volume (P<0.001). There was no disparity observed in pulmonary function decline at three months after the surgery between the two cohorts.</p><p><strong>Conclusions: </strong>The watershed analysis with ICG fluorescence staining is associated with less operating time, fewer postoperative complications, and a lower risk of postoperative air leakage in complex pulmonary segmentectomy. The impact on pulmonary function was comparable to the traditional method. These findings suggest that the watershed analysis with ICG fluorescence staining is a more promising, safe, and effective approach for complex pulmonary segmentectomy.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"16 11","pages":"7697-7708"},"PeriodicalIF":2.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: The quality of life of patients with chronic obstructive pulmonary disease: a bibliometric analysis.","authors":"","doi":"10.21037/jtd-2024-06","DOIUrl":"10.21037/jtd-2024-06","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21037/jtd-24-591.].</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"16 11","pages":"8156-8157"},"PeriodicalIF":2.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of vitamin A in relation to childhood asthma with hypertension: a cross-sectional study of the NHANES database.","authors":"Ling Li, Shirui Zhu, Mei Xue","doi":"10.21037/jtd-24-641","DOIUrl":"10.21037/jtd-24-641","url":null,"abstract":"<p><strong>Background: </strong>Recent studies have reported that diet can modulate the associations between risk factors and childhood metabolic diseases. Herein, this study aims to explore the role of dietary vitamin A (VA) in relation to asthma with hypertension in children and adolescents, and further provide some information on dietary aspect for the prevention of asthma related hypertension.</p><p><strong>Methods: </strong>In this cross-sectional study, data of 9,448 children and adolescents were obtained from the National Health and Nutrition Examination Survey (NHANES) database for the period of 2007 to 2018. Weighted univariate logistic regression analysis was used for covariates screening, and associations of dietary VA and asthma with hypertension were explored through weighted univariate and multivariate logistic regression analyses. Odds ratios (ORs) with 95% confidence intervals (CIs) were used as evaluation indexes. Besides, subgroup analyses of age, gender, and body mass index (BMI) were also performed.</p><p><strong>Results: </strong>There were a total of 546 participants with hypertension in the study cohort. Children and adolescents with asthma had higher odds of hypertension than non-asthma individuals after covariates adjustment (OR =1.35, 95% CI: 1.03-1.78). When there were deficient dietary VA intakes, having asthma was significantly linked to higher odds of hypertension comparing to non-asthma individuals (OR =1.46, 95% CI: 1.07-1.99). Additionally, the potential beneficial effect of sufficient dietary VA intakes on hypertension related asthma was found in aged ≥13 years old (OR =1.65, 95% CI: 1.21-2.26), male (OR =1.59, 95% CI: 1.09-2.33), and underweight/normal weight (OR =1.97, 95% CI: 1.14-3.43) subgroups.</p><p><strong>Conclusions: </strong>Children and adolescents having asthma seemed to have higher odds of hypertension, and sufficient dietary VA intakes may help reduce the risk of asthma related hypertension. However, the causal effect of dietary VA intakes on this correlation needs further clarification.</p>","PeriodicalId":17542,"journal":{"name":"Journal of thoracic disease","volume":"16 11","pages":"7271-7281"},"PeriodicalIF":2.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}